Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment.
Publication
, Journal Article
Jiménez-Expósito, MJ; Torres, G; Baraldés, A; Benito, N; Marco, F; Paré, JC; Moreno, A; Claramonte, X; Mestres, CA; Almela, M; Pérez, N ...
Published in: Clin Infect Dis
October 1, 2004
Conventional antifungal therapy for fungal endocarditis has been associated with a poor cure rate. Therefore, combined medical and surgical therapy has been recommended. However, new potent antifungal agents, such as echinocandins, could increase the medical options and, in some cases, avoid the need for surgery. We report a case of Candida endocarditis treated successfully without valve replacement with intravenous liposomal amphotericin B (total dose, 4 g) and intravenous caspofungin (a 100-mg loading dose followed by 50 mg per day for 8 weeks) as induction therapy and intravenous caspofungin (100 mg 3 times per week for 12 weeks) as maintenance therapy.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
October 1, 2004
Volume
39
Issue
7
Start / End Page
e70 / e73
Location
United States
Related Subject Headings
- Peptides, Cyclic
- Microbiology
- Lipopeptides
- Humans
- Female
- Endocarditis
- Echinocandins
- Drug Therapy, Combination
- Caspofungin
- Candidiasis
Citation
APA
Chicago
ICMJE
MLA
NLM
Jiménez-Expósito, M. J., Torres, G., Baraldés, A., Benito, N., Marco, F., Paré, J. C., … Miró, J. M. (2004). Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis, 39(7), e70–e73. https://doi.org/10.1086/424018
Jiménez-Expósito, M. J., G. Torres, A. Baraldés, N. Benito, F. Marco, J. C. Paré, A. Moreno, et al. “Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment.” Clin Infect Dis 39, no. 7 (October 1, 2004): e70–73. https://doi.org/10.1086/424018.
Jiménez-Expósito MJ, Torres G, Baraldés A, Benito N, Marco F, Paré JC, et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis. 2004 Oct 1;39(7):e70–3.
Jiménez-Expósito, M. J., et al. “Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment.” Clin Infect Dis, vol. 39, no. 7, Oct. 2004, pp. e70–73. Pubmed, doi:10.1086/424018.
Jiménez-Expósito MJ, Torres G, Baraldés A, Benito N, Marco F, Paré JC, Moreno A, Claramonte X, Mestres CA, Almela M, García de la María C, Pérez N, Schell WA, Corey GR, Perfect J, Jiménez de Anta MT, Gatell JM, Miró JM. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis. 2004 Oct 1;39(7):e70–e73.
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
October 1, 2004
Volume
39
Issue
7
Start / End Page
e70 / e73
Location
United States
Related Subject Headings
- Peptides, Cyclic
- Microbiology
- Lipopeptides
- Humans
- Female
- Endocarditis
- Echinocandins
- Drug Therapy, Combination
- Caspofungin
- Candidiasis